D
Sell
3/21/2025Upgraded
ARS Pharmaceuticals, Inc. (SPRY) was upgraded to D+ from D- on 3/21/2025 due to a substantial increase in the growth index, total return index and efficiency index. Total revenue increased 4,086.7% from $2.07M to $86.58M, operating cash flow increased 390.34% from -$14.47M to $42M, and net income increased 361.05% from -$19.13M to $49.93M.
D
Sell
1/17/2024Upgraded
ARS Pharmaceuticals, Inc. (SPRY) was upgraded to D- from E+ on 1/17/2024 due to an increase in the volatility index.
E
Sell
11/28/2023Downgrade
ARS Pharmaceuticals, Inc. (SPRY) was downgraded to E+ from D- on 11/28/2023 due to a decline in the total return index and valuation index.
D
Sell
11/13/2023Upgraded
ARS Pharmaceuticals, Inc. (SPRY) was upgraded to D- from E+ on 11/13/2023 due to a noticeable increase in the growth index, volatility index and solvency index. Operating cash flow increased 23.43% from -$16.67M to -$12.76M, earnings per share increased from -$0.183 to -$0.1555, and EBIT increased 12.74% from -$20.6M to -$17.98M.
E
Sell
11/9/2023Downgrade
ARS Pharmaceuticals, Inc. (SPRY) was downgraded to E+ from D- on 11/9/2023 due to a major decline in the efficiency index, volatility index and growth index. Total revenue declined 50% from $20 to $10, operating cash flow declined 34.11% from -$12.43M to -$16.67M, and net income declined 16.1% from -$14.96M to -$17.37M.
D
Sell
8/1/2023Upgraded
ARS Pharmaceuticals, Inc. (SPRY) was upgraded to D- from E+ on 08/01/2023.
E
Sell
7/19/2023Upgraded
ARS Pharmaceuticals, Inc. (SPRY) was upgraded to E+ from E on 7/19/2023 due to an increase in the volatility index.
E
Sell
6/14/2023Downgrade
ARS Pharmaceuticals, Inc. (SPRY) was downgraded to E from E+ on 6/14/2023 due to a large decline in the volatility index, solvency index and valuation index. The quick ratio declined from 50.59 to 26.94.
E
Sell
5/1/2023Upgraded
ARS Pharmaceuticals, Inc. (SPRY) was upgraded to E+ from E on 5/1/2023 due to a significant increase in the solvency index, total return index and valuation index. The quick ratio increased from 4.53 to 50.59.
E
Sell
2/6/2023None
ARS Pharmaceuticals, Inc. (SPRY) was downgraded to E from U on 02/06/2023.
